Fatty acid binding protein 5 regulates docetaxel sensitivity in taxane-resistant prostate cancer cells
PLOS ONE · 05.10.2023 · 18 (10) · e0292483
DOI: 10.1371/journal.pone.0292483 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, online erschienen am 05.10.2023. Verfasst von Andrew Hillowe und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, Renaissance School of Medicine, Stony Brook University, Stony Brook, New York, United States of America. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Prostatic Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
Prostate cancer is a leading cause of cancer-related deaths in men in the United States. Although treatable when detected early, prostate cancer commonly transitions to an aggressive castration-resistant metastatic state. While taxane chemotherapeutics such as docetaxel are mainstay treatment options for prostate cancer, taxane resistance often develops. Fatty acid binding protein 5 (FABP5) is an intracellular lipid chaperone that is upregulated in advanced prostate cancer and is implicated as a key driver of its progression. The recent demonstration that FABP5 inhibitors produce synergistic inhibition of tumor growth when combined with taxane chemotherapeutics highlights the possibility that FABP5 may regulate other features of taxane function, including resistance. Employing taxane-resistant DU145-TXR cells and a combination of cytotoxicity, apoptosis, and cell cycle assays, our findings demonstrate that FABP5 knockdown sensitizes the cells to docetaxel. In contrast, docetaxel potency was unaffected by FABP5 knockdown in taxane-sensitive DU145 cells. Taxane-resistance in DU145-TXR cells stems from upregulation of the P-glycoprotein ATP binding cassette subfamily B member 1 (ABCB1). Expression analyses and functional assays confirmed that FABP5 knockdown in DU145-TXR cells markedly reduced ABCB1 expression and activity, respectively. Our study demonstrates a potential new function for FABP5 in regulating taxane sensitivity and the expression of a major P-glycoprotein efflux pump in prostate cancer cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Anesthesiology, Renaissance School of Medicine, Stony Brook University, Stony Brook, New York, United States of America.
- Department of Applied Mathematics and Statistics, Stony Brook University, Stony Brook, New York, United States of America.
- Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, United States of America.
- Department of Chemistry, Stony Brook University, Stony Brook, New York, United States of America.
- Institute of Chemical Biology and Drug Discovery, Stony Brook University, Stony Brook, New York, United States of America.
- Department of Medicine, Renaissance School of Medicine, Stony Brook University, Stony Brook, New York, United States of America.
ORCID-Profile: Andrew Hillowe, Agnieszka Bialkowska, Martin Kaczocha
Förderung
- NCI NIH HHS
- National Cancer Institute
Zitieren
APA
Hillowe, A., Gordon, C., Wang, L., Rizzo, R. C., Trotman, L. C., Ojima, I., Bialkowska, A., & Kaczocha, M. (2023). Fatty acid binding protein 5 regulates docetaxel sensitivity in taxane-resistant prostate cancer cells. PLOS ONE, 18(10), e0292483. https://doi.org/10.1371/journal.pone.0292483
Vancouver
Hillowe A, Gordon C, Wang L, Rizzo RC, Trotman LC, Ojima I, et al. Fatty acid binding protein 5 regulates docetaxel sensitivity in taxane-resistant prostate cancer cells. PLOS ONE. 2023;18(10):e0292483. doi:10.1371/journal.pone.0292483
BibTeX
@article{Hillowe2023,
author = {Hillowe, Andrew and Gordon, Chris and Wang, Liqun and Rizzo, Robert C and Trotman, Lloyd C and Ojima, Iwao and Bialkowska, Agnieszka and Kaczocha, Martin},
title = {Fatty acid binding protein 5 regulates docetaxel sensitivity in taxane-resistant prostate cancer cells},
journal = {PLOS ONE},
year = {2023},
volume = {18},
number = {10},
pages = {e0292483},
doi = {10.1371/journal.pone.0292483}
}
EUVIMED